Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Nafise, Salek"'
Autor:
Sara Vosoughi, Nafise Salek, Hassan Yousefnia, Milad Delavari, Seyed Mahmoud Reza Aghamiri, Hassan Ranjbar
Publikováno v:
Current Radiopharmaceuticals. 16:64-70
Background: HYNIC – Bombesin (BBN) is a potential peptide for targeted radionuclide therapy in gastrin-releasing peptide receptor (GRPr)-positive malignancies. The 188Re-HYNIC-BBN is a promising radiopharmaceutical for use in prostate cancer therap
Autor:
Ali Bahrami Samani, Sara Vosoughi, Nafise Salek, Mohammad Ghannadi Maragheh, Simindokht Shirvani Arani
Publikováno v:
Current Radiopharmaceuticals. 15:56-62
Background: Due to the suitable nuclear decay characteristics, 177Lu is an attractive radionuclide for various therapeutic applications. The non-carrier added form of 177Lu has drawn many attention because of its high specific activity needed in radi
Autor:
Nafise Salek, Sara Vosoughi, Saeedeh Toorchi Roudsari, Simindokht Shirvani Arani, Mohsen Mehrabi, Reza Davarkhah
Publikováno v:
Brazilian Journal of Physics. 53
Publikováno v:
Journal of Engineering Mathematics. 138
Publikováno v:
Nuclear Medicine Communications. 42:951-963
Many human cancers predominantly metastasize to the bone which causes bone pain and other symptoms. However, the management of bone metastases is challenging. Radionuclide therapy using low-energy beta-emitting radionuclides has yielded encouraging r
Autor:
Sara Vosoughi, Simindokht Shirvani Arani, Ali Bahrami Samani, Nafise Salek, Mohammad Ghannadi Maragheh
Publikováno v:
Journal of Radioanalytical and Nuclear Chemistry. 326:813-821
In this study, a possible therapeutic agent was developed owning to attractive characteristic of 166Dy/166Ho in-vivo generator and tumor targeting of 5,10,15,20-tetrakis(phenyl)porphyrin (TPP). ITLC of the final formulation indicated RCP more than 97
Publikováno v:
Annals of Nuclear Energy. 181:109547
Autor:
Sara, Vosoughi, Nafise, Salek, Simindokht Shirvani, Arani, Ali Bahrami, Samani, Mohammad Ghannadi, Maragheh
Publikováno v:
Current radiopharmaceuticals. 15(1)
Due to the suitable nuclear decay characteristics,Among the various separation methods, the electro-amalgamation separation method has got a large potential for large scale production. Li presence is a significant problem in this separation method, w
Autor:
Mohsen Mehrabi, Mohammad Ghannadi Maraghe, Simindokht Shirvani Arani, Ali Bahrami Samani, Nafise Salek, Sara Vosoghi
Publikováno v:
Current Radiopharmaceuticals. 11:116-122
Background and objective Skeletal uptake of 90Y-1,4,7,10-tetraazacyclododecane-1,4,7,10- tetramethylene-phosphonate (DOTMP) is used to deliver high doses of this radiopharmaceutical to the bone marrow. Methods In this research, carrier-free (c.f.) 90
Publikováno v:
Separation and Purification Technology. 279:119701
The present study is aimed to produce the europium-free 153Sm by electro amalgamation process. For this purpose, the production of radioactive isotope 153Sm and its impurities were theoretically investigated by MATLAB software. The produced impuritie